Ginkgo Bioworks (DNA) Q2 2026 earnings summary

Executive summary

• Strategic focus shifted to autonomous labs, consolidating R&D services onto a single large platform, with Nebula in Boston as a flagship system operating 24/7 with 105 racks, targeting biopharma, national labs, and research universities.

• Significant government contracts were secured to build autonomous labs at MIT, Caltech, Maryland, and Northwestern, expanding reach into academic research and training.

• The company completed the divestiture of its Biosecurity business in April 2026, now reported as discontinued operations, resulting in a $24.5M gain on deconsolidation.

• Operations are now focused solely on autonomous labs and related services, with a single reportable segment post-divestiture.

• U.S. government and NSF investments in autonomous lab infrastructure align with the company's growth strategy.

Financial highlights

• Q2 2026 revenue was $20.2 million, down 48% year-over-year; first six months revenue was $39.6 million, down 49% year-over-year.

• Net loss from continuing operations was $57.3 million in Q2 2026, compared to $53.2 million in Q2 2025.

• Adjusted EBITDA for Q2 2026 was $(36.3) million, compared to $(25.4) million in Q2 2025.

• Cash, cash equivalents, and marketable securities totaled $302.2 million as of June 30, 2026, with $87 million in restricted cash.

• Cash burn for Q2 2026 was $45 million; for the first half, $93 million, a 3% decrease year-over-year.

Outlook and guidance

• Full-year 2026 total cash burn is expected to be between $125 million and $150 million, reaffirmed by management.

• Management expects expenditures to exceed revenue for at least the next 12 months, with sufficient liquidity to fund operations.

• Focus for 2026 is on cost efficiency and strategic investment in autonomous lab capabilities and customer services.